What is Innoviva, Inc.'s market cap?

Innoviva, Inc. (INVA) has a market capitalization of $1.6B and trades on NASDAQ.

What is Innoviva, Inc.'s revenue and profitability?

Innoviva, Inc. generated $420.7M in trailing twelve-month revenue with net income of $504.3M, representing a net margin of 119.9%. Gross margin stands at 73.7%, with free cash flow of $197.1M. These figures are based on the Q1 2026 filing.

Who are Innoviva, Inc.'s competitors?

Innoviva, Inc.'s key competitors include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., and others. These companies compete in similar markets and product categories.

Who does Innoviva, Inc. partner with?

Innoviva, Inc.'s notable partners include GSK, Basilea Pharmaceutica Ltd, Everest Medicines Limited, and others.

What subsidiaries does Innoviva, Inc. have?

Innoviva, Inc.'s subsidiaries include Entasis Therapeutics, La Jolla Pharmaceutical, Tetraphase Pharmaceuticals, Inc., and others.

Where is Innoviva, Inc. headquartered?

Innoviva, Inc. is headquartered in United States of America and employs approximately 112 people. It has been publicly traded since 2004.

Innoviva, Inc.

INVA

Market cap

$1.57B+35.9%

Revenue$420.7M+13.8%

Net income$504.3M+944%

Free cash flow$197.1M+21.5%

EPS (diluted)$6.02+727%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$98.0MMiss by $3.6M EPS$0.44Beat by $0.01

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$111.0M

EPS estimate$0.44

Financials

Q1 2026

Income statement

See full

Revenue$98.0M+10.6%

Gross profit$75.8M+3.4%

Operating income$38.2M-7.9%

Net income$186.6M+501%

EPS (diluted)$2.22+400%

Balance sheet

See full

Cash & equivalents$603.1M+89.0%

Total debt$269.4M-40.3%

Total equity$1.3B—

Total assets$1.8B+46.4%

Cash flow

See full

Operating cash flow$35.3M-27.4%

CapEx$492.0K—

Free cash flow$34.8M-28.4%

Valuation & ratios

Valuation

See full

Market cap$1.57B+35.9%

Enterprise value$1.24B+1.7%

P/E3.1×-27.0×

P/S3.7×+0.6×

Profitability

See full

Gross margin73.7%-9.9pp

Operating margin38.1%-11.2pp

Net margin119.9%+107pp

Returns & leverage

See full

Debt / equity0.2×—

Current ratio21.1×+18.7×

Competitors

By market cap

AbbVie$453.91B+36.3%

Merck & Co.$322.95B+53.0%

Pfizer$140.61B+1.7%

Royalty Pharma$26.0B+66.7%

Insmed$22.7B+17.5%

Ligand Pharmaceuticals$6.0B+129%

Innoviva, Inc.$1.6B+35.1%

Savara$1.1B+142%

By revenue growth

Insmed+115%

Ligand Pharmaceuticals+51.2%

Innoviva, Inc.+13.8%

By net margin

Innoviva, Inc.119.89%+136pp

Ligand Pharmaceuticals55.95%+129pp

Royalty Pharma33.9%-14.4pp

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

AbbVie5.79%-1.5pp

Insmed-144.44%+121pp

Savara-19,305.06%—

Profile

Innoviva, Inc. is a diversified biopharmaceutical company that operates a dual-model business consisting of a high-margin respiratory royalty portfolio and a wholly owned specialty therapeutics platform. The company focuses on the development and commercialization of critical care and infectious disease treatments for the hospital setting, while leveraging long-term royalty streams from partnered respiratory assets. Innoviva actively manages a portfolio of strategic healthcare investments to drive long-term shareholder value through capital allocation in areas of significant unmet medical need.

Competitive position

Innoviva holds a leading position in the niche critical care and infectious disease market while maintaining a significant royalty interest in established global respiratory franchises.

GeographiesUnited States, European Union, China, Global

Customer segmentsHospitals, Pharmaceutical companies

Business modelRoyalty management, Product commercialization, Strategic investment

SuppliersContract manufacturing organizations (CMOs), Active pharmaceutical ingredient (API) suppliers, Clinical research organizations

CustomersHospitals, Specialty pharmacies, Wholesale distributors, International sub-licensees

CountryUnited States of America

Listed2004

Employees112.0

CEOPavel Raifeld

SectorHealthcare

IndustryBiotechnology

Websiteinva.com

FilingsSEC EDGAR

Ask your AI about Innoviva, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Innoviva, Inc.'s market cap?: Innoviva, Inc. (INVA) has a market capitalization of $1.6B and trades on NASDAQ.
What is Innoviva, Inc.'s revenue and profitability?: Innoviva, Inc. generated $420.7M in trailing twelve-month revenue with net income of $504.3M, representing a net margin of 119.9%. Gross margin stands at 73.7%, with free cash flow of $197.1M. These figures are based on the Q1 2026 filing.
Who are Innoviva, Inc.'s competitors?: Innoviva, Inc.'s key competitors include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., and others. These companies compete in similar markets and product categories.
Who does Innoviva, Inc. partner with?: Innoviva, Inc.'s notable partners include GSK, Basilea Pharmaceutica Ltd, Everest Medicines Limited, and others.
What subsidiaries does Innoviva, Inc. have?: Innoviva, Inc.'s subsidiaries include Entasis Therapeutics, La Jolla Pharmaceutical, Tetraphase Pharmaceuticals, Inc., and others.
Where is Innoviva, Inc. headquartered?: Innoviva, Inc. is headquartered in United States of America and employs approximately 112 people. It has been publicly traded since 2004.